These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17419)

  • 21. 1.2-Anellated 1.4-benzodiazepine derivatives--a new class of antipsychotics.
    Ruhland M; Liepmann H; Muesch HR
    Pharmacopsychiatry; 1985 Jan; 18(1):174-7. PubMed ID: 2859621
    [No Abstract]   [Full Text] [Related]  

  • 22. Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Adv Biochem Psychopharmacol; 1980; 24():335-40. PubMed ID: 7190762
    [No Abstract]   [Full Text] [Related]  

  • 23. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-or apomorphine-induced "Cheroing" and "agitation" in rats.
    Janssen PA; Niemegeers CJ; Schellekens KH; Lenaerts FM
    Arzneimittelforschung; 1967 Jul; 17(7):841-54. PubMed ID: 5632842
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacological vs. clinical physiognomy of neuroleptics, with special reference to their sedative and antipsychotic effects.
    Nielsen IM
    Acta Psychiatr Belg; 1974 Sep; 74(5):473-84. PubMed ID: 4471027
    [No Abstract]   [Full Text] [Related]  

  • 25. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological studies on CS-430, a new psychotropic agent.
    Kamioka T; Nakayama I; Hara T; Takagi H
    Arzneimittelforschung; 1978; 28(5):838-47. PubMed ID: 35173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB; Fuxe K; Werge T; Gerlach J
    Behav Pharmacol; 2002 Dec; 13(8):639-44. PubMed ID: 12478214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical characteristics of D1 dopamine receptors: relationship to behavior and schizophrenia.
    Creese I; Hess EJ
    Clin Neuropharmacol; 1986; 9 Suppl 4():14-6. PubMed ID: 2882838
    [No Abstract]   [Full Text] [Related]  

  • 29. Dopamine-sensitive adenylate cyclase and dopamine/neuroleptic receptor binding: effect of neuroleptic drugs.
    Marshall AM; Mishra RK
    Adv Biochem Psychopharmacol; 1980; 24():153-7. PubMed ID: 6105772
    [No Abstract]   [Full Text] [Related]  

  • 30. Dopamine receptor mechanisms: behavioral and electrophysiological studies.
    Ungerstedt U; Ljungberg T; Schultz W
    Adv Biochem Psychopharmacol; 1978; 19():311-21. PubMed ID: 29451
    [No Abstract]   [Full Text] [Related]  

  • 31. Inhibition of circling behavior by neuroleptic drugs in mice with unilateral 6-hydroxydopamine lesions of the striatum.
    Pycock C; Tarsy D; Marsden CD
    Psychopharmacologia; 1975 Dec; 45(2):211-9. PubMed ID: 1240638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychopharmacological agents and the cyclic AMP system of rat brain.
    Uzunov P; Weiss B
    Adv Cyclic Nucleotide Res; 1972; 1():435-53. PubMed ID: 4146714
    [No Abstract]   [Full Text] [Related]  

  • 33. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological effects of Ro 22-1319: a new antipsychotic agent.
    Davidson AB; Boff E; MacNeil DA; Wenger J; Cook L
    Psychopharmacology (Berl); 1983; 79(1):32-9. PubMed ID: 6132425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An experimental model of tardive dyskinesia.
    Klawans HL; Rubovits R
    J Neural Transm; 1972; 33(3):235-46. PubMed ID: 4674512
    [No Abstract]   [Full Text] [Related]  

  • 36. Predictability and specificity of behavioral screening tests for neuroleptics.
    Worms P; Lloyd KG
    Pharmacol Ther B; 1979; 5(1-3):445-50. PubMed ID: 40263
    [No Abstract]   [Full Text] [Related]  

  • 37. The mechanism of action of amantadine in Parkinsonism: a review.
    Bailey EV; Stone TW
    Arch Int Pharmacodyn Ther; 1975 Aug; 216(2):246-62. PubMed ID: 1180616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological profile of a new psychotherapeutic agent: 4-p-fluorophenyl-5-N(N'-o-methoxyphenyl)piperazinoethyl-4-oxazolin-2-one (LR 511).
    Fregnan GB; Vidali M
    Pharmacology; 1977; 15(6):485-502. PubMed ID: 563604
    [No Abstract]   [Full Text] [Related]  

  • 39. 5,8-Disubstituted 1-aminotetralins. A class of compounds with a novel profile of central nervous system activity.
    Sarges R; Tretter JR; Tenen SS; Weissman A
    J Med Chem; 1973 Sep; 16(9):1003-11. PubMed ID: 4795663
    [No Abstract]   [Full Text] [Related]  

  • 40. Importance of O-methylation in dopamine-induced motor and behavioral phenomena.
    Furgeson MD; Dill RE; Dorris RL
    Brain Res; 1976 Mar; 105(1):163-7. PubMed ID: 3267
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.